IPSC
Income statement / Annual
Last year (2024), Century Therapeutics, Inc.'s total revenue was $6.59 M,
an increase of 194.81% from the previous year.
In 2024, Century Therapeutics, Inc.'s net income was -$126.57 M.
See Century Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$6.59 M |
$2.24 M |
$5.20 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$4.58 M
|
$1.75 M
|
$249.00 K
|
| Gross Profit |
$6.59 M
|
$2.24 M
|
$5.20 M
|
-$4.58 M
|
-$1.75 M
|
-$249.00 K
|
| Gross Profit Ratio |
1
|
1
|
1
|
0
|
0
|
0
|
| Research and Development Expenses |
$107.24 M
|
$92.71 M
|
$97.17 M
|
$75.65 M
|
$39.68 M
|
$14.27 M
|
| General & Administrative Expenses |
$33.16 M
|
$34.71 M
|
$31.86 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$33.16 M
|
$34.71 M
|
$31.86 M
|
$14.65 M
|
$7.74 M
|
$5.52 M
|
| Other Expenses |
$4.33 M
|
$21.37 M
|
$10.00 M
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$144.73 M
|
$148.78 M
|
$139.03 M
|
$90.30 M
|
$47.42 M
|
$19.78 M
|
| Cost And Expenses |
$144.73 M
|
$148.78 M
|
$139.03 M
|
$94.88 M
|
$49.18 M
|
$20.03 M
|
| Interest Income |
$13.01 M
|
$12.68 M
|
$2.99 M
|
$898.00 K
|
$704.00 K
|
$1.21 M
|
| Interest Expense |
$0.00
|
$540.00 K
|
$0.00
|
$1.28 M
|
$381.00 K
|
$0.00
|
| Depreciation & Amortization |
$13.30 M
|
$13.04 M
|
$8.44 M
|
$4.58 M
|
$1.75 M
|
$249.00 K
|
| EBITDA |
-$111.47 M |
-$121.21 M |
-$121.20 M |
-$89.92 M |
-$51.44 M |
-$244.52 M |
| EBITDA Ratio |
-16.92
|
-54.23
|
-23.31
|
0
|
0
|
0
|
| Operating Income Ratio |
-20.96
|
-65.57
|
-25.74
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$13.36 M
|
$11.75 M
|
$2.99 M
|
-$898.00 K
|
-$4.40 M
|
-$224.74 M
|
| Income Before Tax |
-$124.78 M
|
-$134.79 M
|
-$130.84 M
|
-$95.78 M
|
-$53.58 M
|
-$244.77 M
|
| Income Before Tax Ratio |
-18.94
|
-60.31
|
-25.17
|
0
|
0
|
0
|
| Income Tax Expense |
$1.79 M
|
$1.88 M
|
$91.00 K
|
$43.00 K
|
$0.00
|
$0.00
|
| Net Income |
-$126.57 M
|
-$136.67 M
|
-$130.93 M
|
-$95.82 M
|
-$53.58 M
|
-$244.77 M
|
| Net Income Ratio |
-19.21
|
-61.15
|
-25.18
|
0
|
0
|
0
|
| EPS |
-1.61 |
-2.3 |
-2.27 |
-1.74 |
-1 |
-4.49 |
| EPS Diluted |
-1.61 |
-2.3 |
-2.27 |
-1.74 |
-1 |
-4.49 |
| Weighted Average Shares Out |
$78.65 M
|
$59.31 M
|
$57.76 M
|
$55.01 M
|
$54.82 M
|
$54.82 M
|
| Weighted Average Shares Out Diluted |
$78.65 M
|
$59.31 M
|
$57.76 M
|
$55.01 M
|
$54.82 M
|
$54.82 M
|
| Link |
|
|
|
|
|
|
